1. Introduction {#sec1-ijms-20-00579}
===============

The prevalence of knee osteoarthritis (OA) has doubled since the mid-twentieth century despite concerted efforts of the research and pharmaceutical industries over the last five decades to develop a therapeutic solution \[[@B1-ijms-20-00579]\]. The global epidemic increase in body mass index (BMI) \[[@B2-ijms-20-00579]\] may well have contributed to this higher incidence of OA \[[@B3-ijms-20-00579],[@B4-ijms-20-00579]\] through a combined effect of joint overloading and adiposity-induced mild inflammation \[[@B5-ijms-20-00579]\]. A Medline literature survey conducted in 2012 on OA and its associated medical costs based on three European, six North American and two Asian studies \[[@B6-ijms-20-00579]\] showed that the annual cost of topical and oral non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of OA was US\$57.38 million. Hip and knee replacement costs exceeded US\$1087.43 million and arthroscopic OA surgery costs exceeded US\$1.71 million. Indirect economic productivity loss due to OA cost over US\$4.1 billion, community services expenditure amounted to US\$5.25 million and social services were estimated to cost US\$275 million \[[@B6-ijms-20-00579]\]. A global OA study published in 2014, which examined the impact of knee and hip OA in 291 countries, confirmed these major socioeconomic impacts \[[@B3-ijms-20-00579]\]. There remains a huge need to fully understand and treat OA and it is only through a better understanding of key disease processes that the research and pharmaceutical communities will be in a better position to finally resolve the therapeutic alleviation of this costly and currently intractable disease.

While OA is a disease of the entire joint, a pathognomonic feature is the progressive breakdown and loss of the articular cartilage leading to joint-organ failure and ultimately the need for replacement. In recent years, the enzymatic pathways responsible for degradation of the two key structural components of cartilage, aggrecan and type-2 collagen, have been defined and highlighted as therapeutic targets \[[@B7-ijms-20-00579]\]. Rather than being a simple bi-molecular composite however, articular cartilage has a complex anisotropic 3-D structure and biochemical composition that enables it to fulfill its demanding biomechanical function in load-bearing joints. Articular cartilage contains several members of the small leucine-rich proteoglycan (SLRP) family with roles in extracellular matrix (ECM) assembly and cellular regulation \[[@B8-ijms-20-00579],[@B9-ijms-20-00579],[@B10-ijms-20-00579]\], and has been shown in genetic studies to be critical to the maintenance of normal cartilage and joint function \[[@B11-ijms-20-00579]\]. Fibromodulin (FMOD) and lumican (LUM) are horse-shoe shaped class II SLRPs \[[@B12-ijms-20-00579]\] that are structurally homologous proteins sharing 47% identity in primary structure \[[@B13-ijms-20-00579],[@B14-ijms-20-00579]\]. Like all class II SLRPs, FMOD and LUM contain 12 leucine-rich repeat domains (LRRs), which provide them with interactive properties with a number of extracellular matrix (ECM) proteins. Foremost in these interactions which organize tissue form and function is the interaction of FMOD and LUM with type I and type II fibrillar collagens. FMOD and LUM interact with the same binding sites on and regulate collagen fibrillogenesis in vitro \[[@B15-ijms-20-00579]\]. FMOD-deficient mice have collagen fibrils of altered dimensions, and display OA-like features in their knee articular cartilage \[[@B16-ijms-20-00579],[@B17-ijms-20-00579]\]. In addition, studies in knock-out mice indicate that LUM and FMOD reciprocally inhibit collagen interactions, through their binding sites on type I collagen \[[@B15-ijms-20-00579]\]. The increased deposition of LUM in FMOD-deficient mice suggests that LUM binds to non-occupied FMOD-binding sites in collagen I \[[@B15-ijms-20-00579]\].

FMOD and LUM are not redundant since they do not share functional equivalence in terms of how they organize ECM proteins. FMOD has N-linked glycosylation sites on Asn 127, 166, 201, 291 and 341, four of these sites are occupied by keratan sulfate (KS) at any one time. LUM contains N-linked KS chains located within the central LRR region at Asn 88, 127, 160, and 252. FMOD and LUM both contain N-terminal sulfated tyrosine residues; FMOD contains up to nine sulfated tyrosines and LUM contains two \[[@B18-ijms-20-00579],[@B19-ijms-20-00579]\]. These are interactive with the heparin-binding proteins Fibroblast growth factor (FGF)-2, Thrombospondin (TSP)-I, MMP-13, the non-collagenous (NC)4 domain of collagen IX, and IL-10, and bind to collagen and promote fibril formation \[[@B20-ijms-20-00579]\]. FMOD sequesters TGF-β in the ECM and controls its bio-availability, binds C1q and activates the complement system \[[@B21-ijms-20-00579],[@B22-ijms-20-00579],[@B23-ijms-20-00579]\]. LUM differs from FMOD in terms of cell interactive properties, being an MMP-14 inhibitor and it impedes tumor cell migration and growth through its interaction with α2β1 integrin which conveys anti-angiogenic properties \[[@B24-ijms-20-00579],[@B25-ijms-20-00579],[@B26-ijms-20-00579]\]. LUM also has novel roles in the innate immune response through interactions with Toll-like receptor-4 (TLR-4). LUM prevents or at least delays cleavage of collagen by MMP-13 in vitro \[[@B27-ijms-20-00579]\].

We and others have shown extensive degradation of SLRPs including FMOD and LUM in OA articular cartilage \[[@B28-ijms-20-00579],[@B29-ijms-20-00579]\]. In contrast to the proteolytic mechanisms for cartilage aggrecan and collagen degradation, the enzymes responsible for SLRP proteolysis in OA are less well-defined. In a study designed to examine the susceptibility of knee articular cartilage ECM components to MMP digestion, pieces of cartilage were used as substrates rather than soluble proteins, and proteomic sequencing was used to identify the unique peptides generated \[[@B30-ijms-20-00579]\]. Peptides arising from biglycan (BGN), decorin (DCN), proline/arginine-rich end leucine-rich repeat protein (PRELP), FMOD and LUM were generated using MMP-2, -3, -8, -9, -12, -13, ADAMTS-4 and ADAMTS-5. ADAMTS-4 was the only MMP which degraded LUM, releasing two small peptides of low abundance. LUM was resistant to degradation by all the MMPs that were examined except MMP-12 which released three peptides. In comparison, FMOD was extensively degraded by all the MMPs tested with as many as 15 peptides generated by ADAMTS-4 and 18 peptides by MMP-12. The tyrosine sulfate-rich region of FMOD is also cleaved by MMP-13 with this event preceding enzymatic attack of the type II collagen fiber \[[@B31-ijms-20-00579]\]. This work has clearly shown that FMOD and LUM have differential susceptibility to a number of enzymes known to be expressed in OA cartilage. The aim of the present study was to extend these previous observations using sequence-specific antibodies to examine FMOD and LUM degradation in OA and in the growth of articular cartilages, to further define the proteolytic pathways responsible for FMOD and LUM turnover in in health and disease.

2. Results {#sec2-ijms-20-00579}
==========

We initially examined the immunolocalization of FMOD and MMP-13-cleaved FMOD in human developmental phalangeal and metatarsal cartilage rudiments and metatarsal growth plates ([Figure 1](#ijms-20-00579-f001){ref-type="fig"}). This demonstrated the prominent distribution of full-length FMOD in the foot rudiment cartilages associated with normal and hypertrophic chondrocytes ([Figure 1](#ijms-20-00579-f001){ref-type="fig"}a,d,g). MMP-13-cleaved FMOD displayed a similar distribution pattern in these tissues but was more prominently produced by the terminal hypertophic chondrocytes of the metatarsal growth plates ([Figure 1](#ijms-20-00579-f001){ref-type="fig"}h). This co-localization with the well-recognized region of MMP-13 activity in the growth plates \[[@B32-ijms-20-00579]\] validated the TsYG11 antibody and the physiological role of FMOD proteolysis in rudiment cartilage development and bone formation.

The visual macroscopic examination of human condyle articular cartilage identified areas of normal glistening macroscopically intact cartilage in the left knee of a 55-year-old male donor ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}a). The right knee of this donor, however, contained extensive areas of surface roughened and fibrillated cartilage ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}b). Four areas of degenerate cartilage and one normal cartilage region in the left knee were subsequently selected and these were extracted with 4 M GuHCl. The constituent FMOD and LUM species in these tissue extracts were identified using Western blotting and specific C-terminal antibodies to FMOD (PR-184) and LUM (PR-353) in normal ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}c) and in fibrillated cartilage ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}d,f). MMP-13-cleaved FMOD species were also identified on blots using pAb TsYG11 ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}e). Very little fragmentation of FMOD was evident in the normal cartilage specimen ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}c) or the fibrillated cartilage zones using pAb PR-184 ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}d). Multiple MMP-13-cleaved FMOD fragments were, however, evident in all four fibrillated cartilage zones examined ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}d). In contrast, fragmentation of LUM was evident in both the normal and fibrillated cartilage zones using pAb-353 ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}e). There was a much more marked difference in LUM fragmentation between topographically-defined fibrillated cartilages, with degradation particularly prominent in zone 3 ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}e). The histological examination of proteoglycan distribution, evident by toluidine blue-fast green staining in normal ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}g) and fibrillated zone 4 ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}j) cartilage regions in the lateral femoral condyles, displayed distinct differences. The cartilage thickness was significantly less in the zone 4 specimen and proteoglycan levels were severely depleted (compare [Figure 2](#ijms-20-00579-f002){ref-type="fig"}g with [Figure 2](#ijms-20-00579-f002){ref-type="fig"}j). Immunolocalization of FMOD and MMP-13-cleaved FMOD in the same cartilage regions demonstrated that full-length FMOD had a prominent distribution in the superficial cartilage with lower epitope levels deeper in the cartilages ([Figure 2](#ijms-20-00579-f002){ref-type="fig"}h,k), whereas MMP-13-cleaved FMOD was prominently distributed in both superficial and deep zones in normal and fibrillated cartilage (compare [Figure 2](#ijms-20-00579-f002){ref-type="fig"}i with [Figure 2](#ijms-20-00579-f002){ref-type="fig"}l). In general full-length and MMP-13-cleaved FMOD was distributed around the cells presumably associated with collagenous networks in the territorial matrix.

[Figure 3](#ijms-20-00579-f003){ref-type="fig"} schematically depicts the amino acid sequences and locations of areas of the FMOD core protein identified by the PR-184 and TsYG11 antibodies ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}a). MMP-13 fragmented FMOD species were identified in extracts of normal non-degenerate and degenerate donor cartilages from total knee replacements donors aged 55, 58, 65, 73, 75 and 83 years of age ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}b). Three prominent FMOD fragments were evident of 54, 45 and 32 kDa in size using the TsYG11 Ab ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}b), while little if any fragmentation was detected using pAb PR-184 although band intensity was decreased in the older specimens ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}c). Overnight enzymatic digestions of macroscopically normal articular cartilage from the femoral condyle of a 55-year-old male donor using MMP-13, ADAMTS-4 and ADAMTS-5 ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}d) generated three FMOD fragments of similar sizes to those present in the OA cartilage extracts ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}b). These fragments were most prominent in the MMP-13 digests and were both retained in the tissue (requiring release by GuHCl extraction) as well as being detected in the digestion media. ADAMTS-4 and ADAMTS-5 also generated FMOD fragments of a similar size and these were detected using pAb TsYG11 but to a lesser extent. The examination of the same digest sample blots with pAb PR-184 again failed to demonstrate FMOD fragmentation ([Figure 3](#ijms-20-00579-f003){ref-type="fig"}e). MMP-13 digests contained no detectable pAb PR-184-positive FMOD band, indicating that this enzymatic treatment degraded the C-terminal epitope. The putative three main enzymatically generated FMOD fragments based on size and differential antibody reactivity are presented schematically in [Figure 3](#ijms-20-00579-f003){ref-type="fig"}f.

The examination of LUM fragmentation in knee cartilage extract samples by immunoblotting demonstrated three prominent LUM fragments using pAb PR-353 ([Figure 4](#ijms-20-00579-f004){ref-type="fig"}a). These were most prominent in the 69--80-year-old cartilage samples. Attempts to generate these LUM fragments by in vitro digestion of cartilage samples with MMP-13, ADAMTS-4 or ADAMTS-5 failed to generate the same LUM fragmentation pattern ([Figure 4](#ijms-20-00579-f004){ref-type="fig"}b). While similar LUM fragments were detected in GuHCl control extracts of cartilage, these fragments were not evident in the MMP-13 digests, suggesting that the fragments may have been further degraded by MMP-13. However, a full-length LUM band was still evident ([Figure 4](#ijms-20-00579-f004){ref-type="fig"}b), suggesting that the full-length protein may be more resistant due to its conformation and/or interaction with and protection by other ECM components. A predominant fragment slightly smaller than the full-length 51 kDa LUM was generated and released from cartilage by ADAMTS-4 digestion, along with minor levels of the other three aforementioned LUM fragments. ADAMTS-5 did not generate appreciable levels of LUM fragments ([Figure 4](#ijms-20-00579-f004){ref-type="fig"}b). The proposed LUM fragments observed are presented schematically in [Figure 4](#ijms-20-00579-f004){ref-type="fig"}c.

It is recognized that the substrate specificity of ADAMTS may be altered with C-terminal truncation of the enzymes \[[@B33-ijms-20-00579]\] which is known to occur though autocatalysis during incubation \[[@B34-ijms-20-00579],[@B35-ijms-20-00579]\]. The examination of the autocatalytic conversion of ADAMTS-4 and ADAMTS-5 demonstrated the generation of a number of smaller molecular weight forms in ADAMTS-4 but to a lesser extent in the ADAMTS-5 preparation ([Figure 5](#ijms-20-00579-f005){ref-type="fig"}a). These samples were nevertheless enzymatically active and cleavage of aggrecan in the cartilage samples used generated the typical BC-3 neoepitopes while MMP-13 or APMA did not ([Figure 5](#ijms-20-00579-f005){ref-type="fig"}b). MMP-13 (and APMA) did, however, generate the characteristic aggrecan MMP-cleavage neoepitopes identified by MAb BC-14 ([Figure 5](#ijms-20-00579-f005){ref-type="fig"}b).

The stimulation of the cultured ovine explants with IL-1α and oncostatin-M (OSM) was used to replicate chondrocyte-driven cartilage matrix degradation. As expected, IL-1/OSM resulted in a significant decline in cartilage sulfated glycosaminoglycan (GAG) levels on day 5--12 of culture, consistent with the stimulation of aggrecanolysis by this treatment ([Figure 6](#ijms-20-00579-f006){ref-type="fig"}a). Under the conditions used, inclusion of an MMP inhibitor failed to prevent this decline in GAG levels as expected with the concentration of PGE3162689 used (300 nM) where MMP-1, -2, -3, -7, -8, -9, -13 and -14 were inhibited but not ADAMTSs \[[@B36-ijms-20-00579],[@B37-ijms-20-00579],[@B38-ijms-20-00579]\]. The cartilage collagen content (as measured by hydroxyproline) was unaffected by IL-1/OSM at day 5 but decreased in association with MMP activation on prolonged stimulation ([Figure 6](#ijms-20-00579-f006){ref-type="fig"}b, 12 days; collagen loss completely abrogated by inclusion of the MMP inhibitor). The immunoblotting of media samples from the explant cultures demonstrated a reduction in FMOD levels only on day 12 and the FMOD band was of a lower molecular weight than in the control cultures ([Figure 6](#ijms-20-00579-f006){ref-type="fig"}c). The inhibition of MMP activity by inclusion of PGE3162689 in the explant cultures prevented this proteolysis of FMOD, confirming that this was driven by MMPs and not ADAMTS.

3. Discussion {#sec3-ijms-20-00579}
=============

SLRPs have important roles to play in the organization of the cartilage ECM and functional roles in cartilage development remodeling and in the pathogenesis of OA \[[@B11-ijms-20-00579]\]. In the present study, immunolocalization of FMOD in the developmental metatarsal and phalangeal rudiment cartilages and metatarsal growth plates of the foot demonstrated that FMOD was expressed by normal chondrocytes during cartilage development and by those chondrocytes undergoing hypertrophy in the growth plates. MMP-13-cleaved FMOD was prominent in the growth plates, which is consistent with MMP-13 as a marker of hypertrophy and with roles for FMOD and MMP-13 in endochondral ossification \[[@B39-ijms-20-00579]\].

In the knee, OA is a progressive degenerative disorder affecting all joint tissues (articular cartilage, meniscus, synovium, subchondral bone, infrapatellar fat pad, ligaments) to variable degrees \[[@B40-ijms-20-00579],[@B41-ijms-20-00579]\]. Historically, the degeneration of articular cartilage has been a major focus of studies on the etiopathogenesis of OA. However, with the appreciation of OA as a multifactorial global disorder and that degenerative changes in cartilage are affected by the synovium, subchondral bone, infra-patellar fat pad, meniscus, ligaments and tendons \[[@B40-ijms-20-00579],[@B41-ijms-20-00579],[@B42-ijms-20-00579],[@B43-ijms-20-00579],[@B44-ijms-20-00579],[@B45-ijms-20-00579],[@B46-ijms-20-00579],[@B47-ijms-20-00579],[@B48-ijms-20-00579],[@B49-ijms-20-00579],[@B50-ijms-20-00579]\], there is now a greater appreciation of the contributions and feedback from and between all these joint tissues in the achievement of optimal knee functional properties \[[@B51-ijms-20-00579],[@B52-ijms-20-00579],[@B53-ijms-20-00579],[@B54-ijms-20-00579]\]. A potential pathway exists whereby joint tissues may interact and contribute to the onset and progression of OA through the generation of a variety of damage-associated molecular pattern molecules (DAMPs) which act through multiple pathways \[[@B55-ijms-20-00579]\]. DAMPs may reside inside the cell or are sequestered in the ECM in the healthy state \[[@B56-ijms-20-00579],[@B57-ijms-20-00579]\] but their release from diseased/pathological tissues by proteases \[[@B58-ijms-20-00579]\] makes them available to interact with pattern recognition receptors such as the Toll-like receptors (TLRs) and other non-immune cell-surface receptors which activate innate immune and inflammatory responses \[[@B59-ijms-20-00579]\]. SLRPs can act as powerful DAMPs following their proteolytic release from the ECM, clustering different types of receptors to orchestrate a host of downstream signaling events \[[@B60-ijms-20-00579],[@B61-ijms-20-00579],[@B62-ijms-20-00579]\].

During OA, active ADAMTS-4, ADAMTS-5 \[[@B63-ijms-20-00579]\], MMP-2, MMP-3, MMP-13, and MMP-14 \[[@B30-ijms-20-00579]\] could potentially release intact or fragmented forms of FMOD and LUM to act as DAMPs activating TLR2 and -4, initiating innate inflammation and pain pathways \[[@B58-ijms-20-00579],[@B62-ijms-20-00579]\]. As shown by the present study, despite significant homology between FMOD and LUM, these SLRPs display differential susceptibilities to degradation by MMP-13, ADAMTS-4 and ADAMTS-5. FMOD is susceptible while LUM is resistant to MMP cleavage, which is potentially related to its identification as an MMP-inhibitor \[[@B64-ijms-20-00579]\]. This inhibitory activity resides in a peptide named lumcorin, located in LRR-9 of LUM \[[@B65-ijms-20-00579]\]. MT1-MMP has been shown to cleave LUM, abrogating the suppressive activity that it displays towards tumor cell colony formation \[[@B66-ijms-20-00579]\]. The tyrosine-rich residues in the N-terminal region of FMOD are sulfated \[[@B18-ijms-20-00579]\], bind collagen enhancing fibril formation \[[@B20-ijms-20-00579]\], and heparin binding bioactive factors \[[@B20-ijms-20-00579]\] but are cleaved by MMP-13 \[[@B67-ijms-20-00579]\]. FMOD in articular cartilage, and meniscus is extensively fragmented in human \[[@B29-ijms-20-00579]\] and animal models \[[@B68-ijms-20-00579]\] of OA. In the present study, intact FMOD was present at a higher density in the superficial region than the interterritorial matrix of knee articular cartilage as previously reported \[[@B69-ijms-20-00579]\]. While similarly present in the superficial zone, MMP-13-cleaved FMOD was also prominent in the deep cartilage regions consistent with cleavage by chondrocyte rather synovial-derived enzymes. While FMOD fragmentation has been reported in RA and OA articular cartilage \[[@B28-ijms-20-00579],[@B70-ijms-20-00579]\] and with ageing \[[@B71-ijms-20-00579]\], we have recently found minimal fragmentation compared with other SLRPs in OA knee menisci and knee and hip articular cartilage when a C-terminal antibody was used for FMOD detection \[[@B72-ijms-20-00579]\]. The present study shows that C-terminal processing of FMOD may have resulted in an inability to detect the processed forms of FMOD using Ab PR 184 in this earlier study.

In cartilage degradation in vitro, FMOD is degraded in bovine nasal cartilage explant cultures stimulated with IL-1 \[[@B67-ijms-20-00579],[@B73-ijms-20-00579]\]. Cleavage in the N-terminal extension of FMOD resulted in the release of all but one of its sulfated tyrosine residues \[[@B67-ijms-20-00579]\]. In-vitro experiments demonstrated that MMP-13 but not MMP-2, -3, -8, or -9, selectively cleaved at this N-terminal site, but only when FMOD was bound to type II collagen and not when in free solution \[[@B67-ijms-20-00579]\]. This work resulted in the development of the MMP-13 neoepitope antibody (TsYG11) to the MMP-13 cleavage sequence in bovine FMOD between residues 63 and 64 at PAY^63^↓A^64^YG \[[@B67-ijms-20-00579]\] that we used this antibody in the current work.

The digestion of the macroscopically intact articular cartilage with MMP-13 generated three TsYG11-positive FMOD fragments of Mw 54, 45 and 32 kDa. Previous studies have demonstrated the cleavage of soluble bovine FMOD by ADAMTS-4 and ADAMTS-5 \[[@B33-ijms-20-00579],[@B74-ijms-20-00579]\]. In the current study, we confirmed that ADAMTS-4 and ADAMTS-5 also generated FMOD fragments of 54 and 45 kDa through cleavage at the MMP-13 sensitive sites (TsYG11-positive). While resistant to MMPs, the examination of LUM fragmentation in ADAMTS-4 and ADAMTS-5 digested cartilage samples identified two prominent fragments of 48 and 45 kDa. These findings are in agreement with an earlier study where cartilage pieces were digested with MMP-2, -3, -8, -9, -12, -13 and ADAMTS-4 and ADAMTS-5 \[[@B30-ijms-20-00579]\].

A single MMP-13 cleavage site has been identified in bovine FMOD, and we show that ADAMTS-4 and ADAMTS-5 also cleave at this site, generating a reduction in size of approximately 5--10 kDa \[[@B33-ijms-20-00579],[@B67-ijms-20-00579],[@B74-ijms-20-00579]\]. A similar fragment was also identified in OA human knee cartilage. These TsYG11-positive fragments most likely arose from proteolysis at the known MMP-13 cleavage site as well as one of several as yet unidentified cleavage sites in the C-terminus and LRRs. In the present study, recombinant MMP-13 and ADAMTS-4 generated a 37 kDa fragment also observed in OA tissues. ADAMTS-4 and ADAMTS-5 also cleave FMOD at the same Tyr-Ala bond as MMP-13, with ADAMTS-5 potentially being more active against FMOD in solution-phase digests \[[@B74-ijms-20-00579],[@B75-ijms-20-00579]\]. Our results demonstrated that ADAMTS-4 degraded FMOD in cartilage, despite ADAMTS-5 showing superior aggrecanolytic activity in vitro. While generated by incubation with recombinant enzymes, stimulation of cartilage explants with IL-1/OSM suggested that chondrocyte-derived MMP-13 and not ADAMTS plays a greater role. Thus, despite the potential for ADAMTS enzymes, and ADAMTS-4 in particular, to cleave FMOD, MMP-13 likely plays a more significant role. Thus, our in vitro data support previous reports \[[@B67-ijms-20-00579],[@B76-ijms-20-00579]\] that cleavage of FMOD occurs after the major breakdown of aggrecan by ADAMTS but before significant MMP-driven collagenolysis has occurred, suggesting that removal of FMOD from the collagen fibril may be a prerequisite for collagen proteolysis. The susceptibility to ADAMTS proteolysis of LUM, which has similar collagen binding, may also contribute to sequential cartilage ECM degradation in OA.

The identification of the specific fragments of FMOD that are released from cartilage may provide useful biomarkers to monitor the progression of cartilage degradation from early stage aggrecan loss to later collagenolysis and to identify therapeutic molecular targets. The differential susceptibility of FMOD and LUM to enzymatic degradation by MMPs observed in the present study was a surprising finding but in keeping with a recent study which demonstrated that LUM was an MMP-14 inhibitor \[[@B64-ijms-20-00579]\]. MMPs are generally considered the physiological modulators of connective tissue composition both in tissue development and in pathological degradation. However, LUM appears to be susceptible to either an MMP other than that which was examined in this study or the cited studies or another class of proteinase. A related SLRP member mimecan/osteoglycin is degraded by BMP-1 which converts it to a form with better interactive properties with collagen fibrils \[[@B77-ijms-20-00579]\]. A similar proteinase may also be responsible for the LUM fragmentation observed in pathological knee cartilage samples.

4. Materials and Methods {#sec4-ijms-20-00579}
========================

4.1. Consumables {#sec4dot1-ijms-20-00579}
----------------

All electrophoresis consumables, pre-poured gels, running buffer concentrates, blotting membranes and pre-stained protein molecular weight standards were obtained from Invitrogen, Mount Vic, Australia. Blotting consumables, NBT/BCIP substrates, alkaline phosphatase labeled secondary antibodies and development buffers were obtained from Bio-rad Laboratories Pty Ltd, Gladesville, NSW 2111, Australia. Chondroitinase ABC (*Proteus vulgaris*), keratanase-I (*Pseudomonas* sp.) and guanidine hydrochloride (GuHCl) were obtained from Sigma-Aldrich Australia, Castle Hill, NSW, Australia. *N*-glycanase (peptide-*N*-glycosidase F) from *E. coli* was obtained from Genzyme, N. Ryde, NSW, Australia. Recombinant human pro-MMP-13 was a generous gift from Professor Gillian Murphy, University of Nottingham, Nottingham, UK Recombinant human ADAMTS-4 and ADAMTS-5 were kindly supplied by Dr Carl Flannery, Wyeth, Cambridge, Mass, USA. Menzel and Glaser SuperFrost ultraPlus, positively-charged microscope slides were obtained from Fisher Scientific, Braunschweig, GmbH. NovaRED peroxidase substrate was obtained from Vector Laboratories (Burlingame, CA, USA). Biotinylated anti-rabbit IgG secondary antibody, avidin HRP conjugate and non-protein block were obtained from Dako, Botany, NSW, Australia. Fetal calf serum was obtained from Trace Biosciences Pty. Ltd., Castle Hill, NSW, Australia.

4.2. Tissues {#sec4dot2-ijms-20-00579}
------------

This study was approved by the Human Research Ethics Committee of the Royal North Shore Hospital; all discarded tissues at the time of knee-joint replacement surgery were obtained with informed consent. This work was covered by two ethics covers (i) NSLHD Protocol 0404-103M (Oct 2004--2008): J Melrose, C Little, D Sonnabend---"Pathobiology of the small leucine rich repeat proteoglycans in cartilage, intervertebral disc and tendon degeneration" for use of discarded human tissues from surgery and by NSLHD Protocol 0308-163M (Sept 2004--2009): J Melrose, C Jackson, J Whitelock---"The role of perlecan in cartilage development" which covered use of human foetal joint tissues.

Cartilage from a total of 25 total knee replacements was collected for this study. Four non-arthritic knees were obtained from The International Institute of Advancement in Medicine (IIAM), Jessup, PA, USA; a division of the Musculoskeletal Foundation. Cartilage from these normal joints was harvested from regions with a normal smooth glistening surface (N) and regions with a dull appearance indicative of surface fibrillation. Human fetal feet (12--14 week gestational age) were obtained at the time of termination of pregnancy with ethical permission. Human fetal feet (*n* = 4) were selected as a tissue to study since we were interested in examining the growth plates as well as chondrocytes in the main rudiment cartilage and these specimens conveniently contain around 30 articulating joints in the one specimen. The growth plate is a well known area of MMP activation and growth plate chondrocyte hypertrophy is associated with MMP-13 activity. Thus, these tissues can be used to demonstrate proof of principle and the authenticity of the antibody preparations. Adult human knees were used since these provide multiple cartilage samples for analysis from morphologically normal and surface abraded OA cartilage regions. Sheep stifle joint control tissues were obtained from related projects in our laboratory for comparative in vitro analyses with IL-1/OSM.

4.3. Antibodies {#sec4dot3-ijms-20-00579}
---------------

Affinity purified rabbit polyclonal antibodies to the C-terminal peptide sequence LRLASLIEI of human FMOD (Ab PR-184) were used as described earlier \[[@B72-ijms-20-00579],[@B78-ijms-20-00579]\]. The anti-C-terminal LUM antibody used in this study was an affinity purified rabbit polyclonal antibody raised against the peptide sequence H-CGGLRVANEVTLN-OH, which comprises an amino terminal cysteine residue used for conjugation to ovalbumin for antibody production, two spacer glycine residues, and the carboxyl terminal 10 amino acids of human, bovine and chick LUM. The anti-LUM antibodies were purified by affinity chromatography using the same immunization peptide as ligand. A rabbit polyclonal antibody (TsYG11) to the ten amino acid linear sequence TYGSPSPPDP C-terminal to the putative MMP-13 cleavage site in human FMOD was generated to examine FMOD core protein fragmentation by Associate Prof Patrik Onnerfjord and Prof Dick Heinegard (deceased) University of Lund, Sweden. Monoclonal antibodies to neoepitope sequences generated by cleavage of aggrecan by ADAMTS (ARGS...; antibody BC-3) or MMPs (FFGV...; BC-14) were provided as hybridoma culture supernatant by Professor Bruce Caterson and Dr Clare Hughes (Cardiff University) and used to confirm that ADAMTS-4 and ADAMTS-5 were enzymatically active prior to digestion of cartilage.

4.4. Extraction of Tissues {#sec4dot4-ijms-20-00579}
--------------------------

The tissues were cut into small pieces using scalpels and extracted with 10 volumes of 4 M guanidine hydrochloride (GuHCl) and 0.5 M sodium acetate, pH 5.8, containing 10 mM EDTA, 20 mM benzamidine and 50 mM 6-aminohexanoic acid using end-over-end mixing for 48 h at 4 °C. The tissue residues were separated from the extracts by centrifugation and discarded. Tissue extracts were dialyzed against 3 changes of milliQ water and freeze dried.

4.5. Chondroitinase ABC, Keratanase-I and N-Glycanase Digestion of Tissue Extracts {#sec4dot5-ijms-20-00579}
----------------------------------------------------------------------------------

The freeze dried tissue extracts were re-dissolved (2 mg dry wt/mL) overnight in 100 mM Tris 0.03 M acetate buffer, pH 6.5, at 4 °C with constant end-over-end mixing and the aliquots (0.5 mL) were digested with chondroitinase ABC (0.1 U) and keratanase-I (0.05 U) overnight at 37 °C. Selected tissue extracts were also digested with N-glycanase (PNGase F, Prozyme laboratories, was obtained through Agilent Technologies, Mulgrave, Vic, Australia Briefly, chondroitinase ABC and keratanase-I digested samples were dialyzed and freeze dried, then re-dissolved in 20 mM sodium phosphate buffer, pH 7.5, (100 µL), before denaturation solution (2% SDS, 1 M 2-mercaptoethanol, 5 µL) was added and the samples were then heated at 100 °C for 5 min. NP-40 detergent (15% *v*/*v*, 5 µL) was then added, followed by N-glycanase (4 µL/20 mU) and then the samples were incubated at 37 °C for 3 h.

4.6. SDS PAGE and Detection of SLRP Fragments by Western Blotting {#sec4dot6-ijms-20-00579}
-----------------------------------------------------------------

Aliquots of the chondroitinase ABC, keratanase-I, II or N-glycanase digested samples, containing tissue extracts from an equivalent wet weight of tissue (0.8 mg/lane), were mixed with 4× LDS PAGE application buffer (35 µL) and 10× reducing agent (15 µL) and re-dispersed in a total volume of 100 µL. The samples were heated at 70 °C for 30 min and then cooled, before 25 µL aliquots were electrophoresed under reducing conditions on 10% NuPAGE Bis-Tris gels at 200 V constant voltage for 50 min using NuPAGE MOPS SDS running buffer. The gels were electroblotted to nitrocellulose membranes (0.22 µm) using NuPAGE transfer buffer supplemented with 10% methanol at 30 V constant voltage for 1 h. SeeBlue-2 pre-stained protein molecular weight standards were also electrophoresed for molecular weight calibration and to assess the blotting transfer efficiency. The blots were initially blocked for 3 h with 5% BSA in 50 mM Tris-HCl 0.15 M NaCl pH 7.2 (TBS) then incubated with either PR-184 (0.5 µg/mL) or TsYG 11 (1/1000 diln) diluted in 2% BSA in TBS overnight at room temp. After a brief rinse in TBS, the goat anti rabbit IgG alkaline phosphatase conjugate diluted in TBS (1/5000 dilution) was added. After a further 1 h, the blots were washed in TBS (3 × 10 min) and the NBT/BCIP substrates were added into the alkaline phosphatase development buffer (0.1 M Tris-HCl pH 9.5 containing 5 mM MgCl~2~) for the detection of immune complexes. After development the blots were rinsed in milliQ distilled water before being dried. Western blots were repeated a minimum of three times and were also conducted omitting the primary antibody to check that no IgG species were present in the tissue extracts which cross-reacted with the conjugated secondary antibodies (false positives).

4.7. Cartilage Digestion with MMP-13, ADAMTS-4 and ADAMTS-5 {#sec4dot7-ijms-20-00579}
-----------------------------------------------------------

Full-thickness articular cartilage (AC) was harvested from macroscopically normal regions of a femoral condyle of a 55 year-old-male cadaver (see [Figure 2](#ijms-20-00579-f002){ref-type="fig"}). The tissue was finely diced and 10 mg wet weight samples were aliquoted into eppendorf tubes. One cartilage sample was extracted directly with 4 M GuHCl buffered in 0.5 M sodium acetate, pH 5.8, containing 10 mM EDTA, 20 mM benzamidine and 50 mM 6-aminohexanoic acid (0.5 mL) with constant end-over-end mixing for 48 h at 4 °C. The extract was then recovered by centrifugation and the tissue residue discarded. In further tubes, diced AC was dispersed in: (i) a solution of 1 mM APMA and MMP-13 (50 µg/mL) in MMP digestion buffer (50 mM Tris HCl, 150 mM NaCl, 5 mM CaCl~2~, 1 mM ZnCl~2~, 0.01% Brij-35 pH 7.5 (0.2 mL)); (ii) 1 mM APMA in MMP digestion buffer; (iii) ADAMTS-4 or (iv) ADAMTS-5 (50 µg/mL) in the same MMP digestion buffer without APMA. After 24 h incubation at 37 °C, the tissue residues were spun down and the digestion buffer was collected. The tissue residues were extracted with 4 M GuHCl + proteinase inhibitors (0.5 mL) for 48 h at 4 °C, and then the extract was collected and the tissue residues were discarded. The 4 M GuHCl extracts and digestion buffer samples were dialyzed against milliQ distilled water then freeze dried. The samples were reconstituted in 50 mM Tris-acetate buffer pH 6.5 (0.2 mL) and the glycosaminoglycan (GAG) content of an aliquot was determined using the 1,9-dimethylmethylene blue metachromatic dye binding assay procedure. Chondroitinase ABC (0.01 U/10 μg GAG), keratanase-I (0.01 U/10 µg GAG) and keratanase-II (0.1 mU/10 µg GAG) were added to the samples and they were digested overnight at 37 °C. 4× LDS PAGE application buffer (80 µL) + 30 µL reducing agent were then added to the digested samples and they were heated on a block at 70 °C for 10 min. The samples were electrophoresed using pre-poured 10% Bis-Tris gels and transferred to nitrocellulose for analysis by Western blotting. Gel loading was 10 µg GAG/lane for BC-3, 20 µg GAG/lane for BC-14, and, for FMOD, the extract or digest supernatant from an equal wet weight of tissue (0.8 mg)/lane. Samples were pre-digested with chondroitinase ABC, and keratanase-I and II as indicated above.

4.8. Ovine Cartilage Explant Cultures {#sec4dot8-ijms-20-00579}
-------------------------------------

Full-depth articular cartilage explants were harvested from the trochlear groove of 6--12-month-old ovine knee joints and cultured at 37 °C, 5% (*v*/*v*) CO~2~ for 48 h in Dulbecco's Modified Eagles Medium (DMEM; Sigma, Castle Hill, NSW, Australia), buffered with sodium bicarbonate 3.7 g/L (Fronine, Riverstone, NSW, Australia) and containing 10% (*v*/*v*) Fetal Calf Serum (FCS; Trace Biosciences Pty. Ltd., Castle Hill, NSW, Australia), 2 mM L-glutamine (ICN Biochemicals Inc., Aurora, OH, USA), and 50 µg/mL Gentamicin (Pharmacia Pty. Ltd., Bentley, WA, Australia). The explants were washed (3 × 5 min) in serum free DMEM and cultured individually in serum-free DMEM ± 5 ng/mL IL-1α plus 50 ng/mL oncostatin M (IL-1/OSM; PeproTech Rocky Hill, NJ 08553, United States) ± 300 nm PGE3162689 (synthesized at Procter and Gamble Pharmaceuticals, Cincinnati, Ohio, USA). As previously described, PGE3162689 at this concentration inhibited MMP-1, -2, -3, -7, -8, -9, -13 and -14 but not ADAMTSs in cartilage explant cultures \[[@B79-ijms-20-00579]\]. The explants were cultured for 5 or 12 days with media changed at 5 and 12 days-(*n* = 8/treatments/time-point). At harvest, the explants (*n* = 6/group) were digested with papain, and the GAG and hydroxyproline content of the tissue digests and associated media were measured \[[@B79-ijms-20-00579]\]. The remaining two randomly selected explants were pooled and extracted with 4 M GuHCl and the chondroitinase- and keratanase-digested extracts were analyzed by Western blotting with an antibody recognizing the C-terminus of bovine FMOD (PR-184) \[[@B76-ijms-20-00579]\] as described above.

4.9. Histological Processing of Specimens {#sec4dot9-ijms-20-00579}
-----------------------------------------

The human fetal feet were fixed in Histochoice for 18 h. Full-thickness slices (3-mm-thick) of adult femoral articular cartilage were fixed for 48 h in 10% neutral buffered formalin. The tissues were then dehydrated in graded ethanol solutions and finally with xylene and embedded in paraffin. The foot blocks underwent surface decalcification in 10 mM EDTA for 2 h prior to sectioning. Four micron vertical microtome sections were prepared and attached to positively charged microscope slides.

4.10. Toluidine Blue Staining of Cartilage Specimens {#sec4dot10-ijms-20-00579}
----------------------------------------------------

The cartilage sections (4 µm) were stained for 10 min with 0.04% (*w*/*v*) toluidine blue in 0.1 M sodium acetate buffer, pH 4.0, to visualize the anionic glycosaminoglycans followed by a 2-min counterstain in 0.1% (*w*/*v*) fast green FCF.

4.11. Immunolocalization of FMOD and MMP-13-Cleaved FMOD in Cartilage Tissue Sections {#sec4dot11-ijms-20-00579}
-------------------------------------------------------------------------------------

The tissue sections were rehydrated through graded ethanol washes and pre-digested with chondroitinase ABC (0.1 U) for 1 h, then with 0.3% H~2~O~2~ for 10 min to inactivate endogenous peroxidase activity and blocked with DAKO non-protein block. The primary antibodies to FMOD (PR-184, 0.5 µg/mL) or MMP-13-cleaved FMOD (TsYG11, 1/1000 dilution) in TBS containing 2% BSA were added to the sections and they were incubated overnight at 4 °C. The sections were then washed in TBS and biotinylated secondary antibody (mouse anti rabbit IgG, 5 µg/mL) was added for 3 h at room temperature. The color development was undertaken with avidin HRP conjugate using NovaRED peroxidase substrate for 20 min at room temperature and the slides were washed and mounted. The negative control sections were also run, omitting primary Ab or by substituting an irrelevant species specific primary antibody for the authentic one. Both yielded negative results.

4.12. Statistical Analyses {#sec4dot12-ijms-20-00579}
--------------------------

The hydroxyproline and sulfated GAG data were tested for significance using the Kruskal--Wallace equality-of-populations rank test in the first instance. If significance was found (*p* \< 0.05), the samples were compared using the Wilcoxon rank-sum test. Within each parameter, the Benjamini--Hochberg post-hoc test was used to correct for false positives. All statistical analyses were performed using STATA 13 statistical software Survey Designs, College Station, Texas 77845, USA: StataCorp LP). Mean ± standard deviation data were plotted in histograms. Each analysis was based on six replicates and the experiment was repeated on at least two further samples. Data were considered significant when test data vs. control data groups displayed *p* \< 0.05.

5. Conclusions {#sec5-ijms-20-00579}
==============

During cartilage development, remodeling, ageing and OA pathology, FMOD and LUM are both proteolytically processed to variable degrees. FMOD was susceptible to fragmentation by MMP-13, ADAMTS-4 and ADAMTS-5, the three major proteinases, which are also active during the development of OA but also with roles during cartilage development and remodeling. LUM, however, was relatively resistant to proteolysis by MMP-13 but was cleaved particularly by ADAMTS-4. While proteolytically susceptible to different exogenously added soluble enzymes, the in vitro stimulation of progressive chondrocyte-driven cartilage catabolism suggested that MMP-13 is the predominant enzyme responsible for cleavage of FMOD, which occurs after ADAMTS-driven aggrecanolysis. LUM and FMOD have roles in innate immune response and may modulate innate immune responses through pattern recognition receptors of relevance in cartilage homeostasis.
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![Macroscopic vertical section through a 14-week gestational age human fetal foot stained with toluidine blue-fast green (macroscopic views) to depict the cartilage rudiments and the areas used for immunolocalization (**a**--**i**). Immunolocalization of fibromodulin (FMOD) (pAb PR-184), scale bar = 100 µm (**a**,**d**,**g**) and MMP-13-cleaved FMOD (pAb TsYG11) (**b**,**e**,**h**) in human fetal (14-week gestational age) metatarsal and phalangeal rudiment cartilage (**a**,**b**; **d**,**e**) and metatarsal growth plates (**g**,**h**). Negative control sections are also depicted for the same cartilage areas (**c**,**f**,**i**). The immunolocalizations are representative of six sections from each sample zone taken from three feet samples.](ijms-20-00579-g001){#ijms-20-00579-f001}

![Macroscopic view of human knee femoral condyles from a 55-year-old male (**a**,**b**) with a normal (N) area devoid of surface fibrillation and four areas of fibrillated cartilage (1--4) which were extracted with 4 M GuHCl and analyzed by Western blotting (**c**,**d**,**e**,**f**) to identify FMOD (pAb PR-184) and MMP-13-cleaved FMOD (pAb TsYG11) and fragmented lumican (LUM) (pAb PR-353) in these regions. Toluidine blue stained proteoglycan distributions in non-fibrillated (**g**) and fibrillated cartilage (**j**) and FMOD (**h**,**k**) and MMP-13-cleaved FMOD (**i**,**l**) were also immunolocalized in full thickness cartilage sections from the non-fibrillated region (N) and fibrillated zone 4 (F). The blots shown are representative of three independent experiments. The immunohistology shown (**g**--**l**) was undertaken on four different tissue sections with qualitatively similar findings to those shown. Scale bar = 100 µm.](ijms-20-00579-g002){#ijms-20-00579-f002}

![Schematic depiction of the epitopes identified by pAbs TsYG11 and PR-184 (**a**) and identification of naturally occurring FMOD fragments in OA knee cartilage from total knee replacement donors aged 59, 65, 75, 77 and 83 years of age using Western blotting and pAbs TsYG11 (**b**) and PR-184 (**c**) and FMOD species generated in vitro by enzymatic digestion using MMP-13, ADAMTS-4 and ADAMTS-5 detected using pAb TsYG11 (**d**) and pAb PR-184. Schematic depiction of the three major in vitro generated FMOD fragments. (**b**--**e**) were repeated three times and similar results were obtained. Schematic (**f**). depicts FMOD fragments identified.](ijms-20-00579-g003){#ijms-20-00579-f003}

![Composite figure depicting the naturally occurring LUM fragments in OA knee articular cartilage from total knee replacement donors aged 55, 65, 69, 75, 77 and 80 years of age (**a**) and released from macroscopically normal knee articular cartilage from the femoral condyle of a 55-year-old donor by enzymatic digestion with MMP-13, ADAMTS-4 or ADAMTS-5 (**b**). Schematic depiction of the major naturally occurring LUM fragments in OA knee articular cartilage, detected by pAb 353 on Western blots (**c**). Blots (**a**) and (**b**) were repeated twice and similar results were obtained in each case.](ijms-20-00579-g004){#ijms-20-00579-f004}

![Assessment of the autocatalytic conversion of ADAMTS-4 and ADAMTS-5 in vitro. The silver-stained lithium dodecyl sulphate polyacrylamide gel electrophoresis (LDS PAGE) gel of the ADAMTS-4 and ADAMTS-5 species present following activation for 16 h. The samples of ADAMTS-4, -5 were incubated at 37 °C in MMP digestion buffer and the aliquots were removed after time zero and 16 h incubation at 37 °C and were then analyzed in pre-poured Bis-Tris 10% NuPAGE gels (0.5 µg/lane) electrophoresed in 3-(N-morpholino) propanesulfonic acid (MOPS) running buffer. The gels were stained with a Novex Silver Stain kit to visualize ADAMTS species (**a**). Western blots demonstrating the generation of the BC-14 MMP neoepitope by MMP-13 digestion of human articular cartilage and generation of the BC-3 aggrecanase neoepitope in aggrecan by the activated ADAMTS-4 and ADAMTS-5 preparations (**b**). Broad range protein molecular weight standards (Novex) were used in lanes 1 and 4 for size calibrations and SeeBlue-2 pre-stained standards for the Western blots. This experiment was repeated twice and similar results were obtained.](ijms-20-00579-g005){#ijms-20-00579-f005}

![Glycosaminoglycan (GAG; **A**) and collagen content (**B**) of ovine articular cartilage explants after 5 or 12 days of culture in Dulbecco's Modified Eagles Medium (DMEM) without (control) or with 5 ng/mL IL-1 and 50 ng/mL oncostatin M (IL-1/OSM) ± 300 nM MMP-inhibitor PGE3162689 (expressed as % of the total in explant plus media; mean ± standard deviation) (*n* = 6). Significant differences between control and treated cultures were defined as \* *p* \< 0.05, \*\* *p* \< 0.01. (**C**) Western blot analysis of the FMOD core protein and the fragments in the cartilage extracts using PR-184, recognizing the C-terminus of FMOD. This blot was repeated three times.](ijms-20-00579-g006){#ijms-20-00579-f006}
